Astellas Pharma Gets CHMP Nod for Padcev-Keytruda Combo in Advanced Bladder Cancer
Astellas Pharma Gets CHMP Nod for Padcev-Keytruda Combo in Advanced Bladder Cancer
安斯泰萊製藥(adr)獲得CHMP批准，用於愛文思控股在晚期膀胱癌中的Padcev-Keytruda組合治療。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊